Skip to main content
Terug
Watch Compare

Acrivon Therapeutics, Inc.

Datakwaliteit: 83%
ACRV
NASDAQ Manufacturing Chemicals
€ 1,64
▲ € 0,03 (1,86%)
6 months return
—
Momentum
Neutral
ROE
-57,36%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-57,36%
Onder sectorgemiddelde (-54,49%)
ROIC-48,23%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,75
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-0,77 | -0,84
Boven sectorgemiddelde (-1,50)
P/B Ratio0,47
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -65,33 M

Price History

Financiële Trends

Koersdoel Analisten

6 analisten
Buy
+601.2%
upside to target
Huidig
€ 1,64
Consensus Target
€ 11,50
€ 7,00
Laag
€ 19,00
Hoog
Vooruitzicht
Forward K/W
-0,84
Forward WPA
-€ 1,86
Omzet Sch.
9,39 M

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,52 · Rev Est: 207.880,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,51 -€ 0,55 -€ 0,47 -€ 0,49 — —
Estimate -€ 0,65 -€ 0,58 -€ 0,58 -€ 0,46 -€ 0,52 -€ 0,55
Verrassing +21,05% +5,71% +18,97% -7,40% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -57,36% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -77,91 M
ROE -57,36% ROA -51,27%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -65,33 M
ROIC -48,23% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 8,75
Debt / Equity N/A Current Ratio 8,75
Interest Coverage N/A Asset Turnover N/A
Working Capital 115,47 M Tangible Book Value 128,60 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,77 · EV/EBITDA: N/A
P/E Ratio -0,77 Forward P/E -0,84
P/B Ratio 0,47 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 6,41 Fwd Earnings Yield N/A
FCF Yield -108,44%
Market Cap 60,25 M Enterprise Value 24,84 M

Per Share

EPS: -2,02 · FCF/Share: -1,69
EPS (Diluted TTM) -2,02 Revenue / Share N/A
FCF / Share -1,69 OCF / Share -1,64
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 83,86% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 83,86%
SBC-Adj. FCF -80,63 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -77,91 M -80,56 M -60,39 M -31,17 M
EPS (Diluted) -2,02 -2,38 -2,74 -7,56
Gross Profit — — — —
Operating Income -84,11 M -89,20 M -67,10 M -32,66 M
EBITDA — — — —
R&D Expenses 59,99 M 63,99 M 46,02 M —
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax 0,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 129,72 M 196,59 M 138,27 M 181,23 M
Total Liabilities 17,20 M 19,80 M 17,07 M 10,75 M
Shareholders' Equity 112,52 M 176,79 M 121,20 M 170,48 M
Total Debt — — — —
Cash & Equivalents 41,50 M 39,82 M 36,02 M 29,52 M
Current Assets 120,45 M 181,63 M 129,69 M 132,10 M
Current Liabilities 15,66 M 17,21 M 13,30 M 6,52 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,8 -1,5
P/B 0,5 1,6
ROE % -57,4 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock
CNCR CNCR
1,14% weight
BRSIX BRSIX
0,15% weight